Cargando…
The direct oral anticoagulants rivaroxaban and dabigatran do not inhibit orthotopic growth and metastasis of human breast cancer in mice
ESSENTIALS: Factor Xa (FXa)‐targeting direct oral anticoagulants (DOACs) reduce venous thromboembolism (VTE). The effects of FXa‐targeting DOACs on cancer progression remain to be studied. In xenograft models, a FXa‐targeting DOAC did not inhibit breast cancer growth and metastasis. A thrombin‐targe...
Autores principales: | Buijs, Jeroen T., Laghmani, El H., van den Akker, Rob F. P., Tieken, Chris, Vletter, Esther M., van der Molen, Kim M., Crooijmans, Juliette J., Kroone, Chantal, Le Dévédec, Sylvia E., van der Pluijm, Gabri, Versteeg, Henri H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6849835/ https://www.ncbi.nlm.nih.gov/pubmed/30929299 http://dx.doi.org/10.1111/jth.14443 |
Ejemplares similares
-
Inter‐ and intra‐individual concentrations of direct oral anticoagulants: The KIDOAC study
por: Toorop, Myrthe M. A., et al.
Publicado: (2021) -
Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran
por: Glund, Stephan, et al.
Publicado: (2019) -
Major bleeding during oral anticoagulant therapy associated with factor V activation by factor Xa
por: Maag, Anja, et al.
Publicado: (2021) -
Structure‐function of anticoagulant TIX‐5, the inhibitor of factor Xa‐mediated FV activation
por: Maag, Anja, et al.
Publicado: (2021) -
Kallikrein augments the anticoagulant function of the protein C system in thrombin generation
por: Wan, Jun, et al.
Publicado: (2021)